RB1 and acute myeloid leukemia: Gombos and colleagues performed a retrospective case-series review of Rb patients who have developed SMNs and reported that there might be an increased risk for acute myelogenous leukemia (AML), an otherwise very rare SMN in long-term Rb survivors, in chemotherapy treated individuals compared to non-chemotherapy treated individuals [65].